Business
Quince Therapeutics Plummets After Late-Stage Trial of A-T Therapy Fails to Hit Targets
Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.